MedTrace Logo

A Study to Investigate Safety, Tolerability and Pharmacokinetics of AZD1446 Administered for 4 Weeks in Elderly Healthy Volunteers

NCT00997308 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 97

Last updated 2010-01-22

No results posted yet for this study

Summary

This study is designed to evaluate the safety, tolerability and pharmacokinetics (PK) of two doses of AZD1446 or placebo in subjects when given for 4 weeks.

Conditions

  • Healthy

Interventions

DRUG

AZD1446

Solution, oral, for 4 weeks

DRUG

Placebo

Sponsors & Collaborators

Principal Investigators

  • Bo Fransson, MD, PhD · AstraZeneca R&DClinical Pharmacology Unit CPUTunavägen 22aS-221 87 LundSweden

  • Björn Paulsson, MD, PhD · AstraZeneca R&D SödertäljeSE-151 85 SödertäljeSweden

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
65 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-10-31
Primary Completion
2009-12-31
Completion
2009-12-31

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00997308 on ClinicalTrials.gov